Illumina (ILMN) : Tekla Capital Management reduced its stake in Illumina by 19.68% during the most recent quarter end. The investment management company now holds a total of 348,864 shares of Illumina which is valued at $47,766,459 after selling 85,477 shares in Illumina , the firm said in a disclosure report filed with the SEC on May 9, 2016.Illumina makes up approximately 2.09% of Tekla Capital Management’s portfolio.
Other Hedge Funds, Including , Congress Asset Management Co boosted its stake in ILMN in the latest quarter, The investment management firm added 3,464 additional shares and now holds a total of 25,465 shares of Illumina which is valued at $3,486,668. Illumina makes up approx 0.09% of Congress Asset Management Co’s portfolio.Proshare Advisors reduced its stake in ILMN by selling 36,310 shares or 18.9% in the most recent quarter. The Hedge Fund company now holds 155,765 shares of ILMN which is valued at $21,917,693. Illumina makes up approx 0.30% of Proshare Advisors’s portfolio.Liberty Mutual Group Asset Management boosted its stake in ILMN in the latest quarter, The investment management firm added 7,563 additional shares and now holds a total of 9,590 shares of Illumina which is valued at $1,349,409. Illumina makes up approx 0.06% of Liberty Mutual Group Asset Management’s portfolio.Bender Robert Associates reduced its stake in ILMN by selling 1,811 shares or 2.89% in the most recent quarter. The Hedge Fund company now holds 60,836 shares of ILMN which is valued at $8,212,252. Illumina makes up approx 5.71% of Bender Robert Associates’s portfolio.
Illumina closed down -0.02 points or -0.01% at $136.92 with 9,16,973 shares getting traded on Friday. Post opening the session at $136.63, the shares hit an intraday low of $135.55 and an intraday high of $138.32 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Shares were Reiterated by Mizuho on May 4, 2016 to “Neutral” and Lowered the Price Target to $ 138 from a previous price target of $150 .Shares were Reiterated by Stifel on May 4, 2016 to “Buy” and Lowered the Price Target to $ 160 from a previous price target of $215 .Shares were Reiterated by Canaccord Genuity on May 4, 2016 to “Hold” and Lowered the Price Target to $ 140 from a previous price target of $160 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.